Roche Diagnostics India’s Elecsys IL-6 test to help identify high risk of severe inflammatory response
- Interleukin 6 (IL-6) is an early indicator for acute inflammation; enables clinical decision-making on managing critically ill patients
- This test can be performed on over 2300 cobas instruments that are available across 500 cities in India
Mumbai, Friday, 26 June 2020: Roche Diagnostics India today highlighted its commitment to enabling access to reliable diagnostic solutions in India. Given the growing need to manage respiratory failure, Roche’s Elecsys IL-6 test measures levels of the biomarker interleukin 6 (IL-6) in human body and can be used to help identify patients who could be at high risk of development of severe respiratory illness.
The test can support physicians, in combination with other examinations and vital signs, to decide early on about treatment management for severe respiratory illness. The levels of IL-6 also helps identify patients who might be at high risk of disease progression.
Dr Sandeep Sewlikar, Medical and Scientific Affairs Head, Roche Diagnostics India, said, “Roche Diagnostics India has been proactively working on addressing the country’s diagnostics need across a whole range of diseases and conditions. Responding to the need to address patient management relating to increasing cases of respiratory distress, I believe that our IL-6 biomarker plays the role of early indicator for acute inflammation in the management of critically ill patients.”
Hospitals and laboratories can run the Elecsys IL-6 test on Roche’s cobas e analysers which are available in around 500 cities across India. These fully automated systems can provide test results in approximately 18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyser.
Dr V. Ramasubramanian, Infectious Diseases Specialist, Apollo Hospitals Chennai said, “Despite a high recovery and a low mortality rate, the number of cases in India is on a steady rise. With an already burdened public healthcare system, it is imperative to evaluate solutions that can facilitate timely treatment to critically ill patients. The IL-6 levels can help in tracking patients with a high risk of forthcoming respiratory failure. An IL-6 testing strategy will help facilitate early detection and timely treatment initiation.”
About Elecsys IL-6
The IL-6 immunoassay is an in vitro diagnostic test for the quantitative determination of IL-6 (interleukin-6) in human serum or plasma. This assay is used in countries accepting CE-mark to aid in the management of critically ill patients, as an early indicator for acute inflammation. This assay can be used to assist in identifying severe inflammatory response in patients to aid in determining the risk of intubation with mechanical ventilation, in conjunction with clinical findings and the results of other laboratory testing. IL-6 is released by immune cells, once they are activated by virus, bacteria or other immune cells. IL-6 acts like a messenger to activate other immune cells to fight the infection. Because IL-6 is released so early during a severe infection, it helps physicians to identify severely ill patients as early as possible. Hospitals and reference laboratories can run the test on Roche’s cobas e analysers, which are widely available around the world. These fully automated systems can provide test results in approximately 18 minutes, with a test throughput of up to 300 tests/hour, depending on the analyser.
About Roche Diagnostics India
Roche Diagnostics India Pvt. Ltd. established in the year 2002 has offices located in Chennai, Delhi, Kolkata and Mumbai with over 400 employees. Our broad range of innovative diagnostic tests and systems play a pivotal role in the groundbreaking area of integrated healthcare solutions and cover early detection, targeted screening, evaluation and monitoring of disease. Roche Diagnostics India works with the objective of “Doing now what patients need next”, thus preparing for the nation’s future healthcare needs. http://www.roche-diagnostics.co.in/
COBAS, ELECSYS, LIAT and TINA-QUANT are trademarks of Roche
For further information, please contact:
Roche Diagnostics India
Magline Rufina FR
Head – Communications
Phone: +91 8879927629
Email: ma[email protected]
Manager – Communications
Phone: +91 9820578421
Email: [email protected]
Read more from the Health Issues India press office here.